title: Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.
abstract: Two molecules - vascular endothelial growth factor involved in new vessels formation and survivin - antiapoptotic protein, reported to be associated with worse prognosis in various malignancies have been chosen for the study. Both are potential target for novel therapies.
  
  
  OBJECTIVE
  Was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival.
  
  
  METHODS
  Formalin-fixed, paraffin-embedded sections from 41 gastric adenocarcinomas were used for immunohistochemical reaction with monoclonal antibodies against vascular endothelial growth factor and survivin. The results were compared with selected clinicopathological features and survival.
  
  
  RESULTS
  Positive immunohistochemical reaction for vascular endothelial growth factor and survivin was revealed in 24 (58,53%) and 30 (73,17%), gastric carcinomas respectively. Vascular endothelial growth factor-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases. Similar, distant metastases were also statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reactions for survivin between less and more advanced cases almost reach statistical significance. The only factors significantly influenced 1, 2 and 3-year survival were vascular endothelial growth factor and survivin status. Statistically significant higher percentage of survival was noted in patients with vascular endothelial growth factor- and survivin-negative tumors.
  
  
  CONCLUSIONS
  It seems that vascular endothelial growth factor and survivin play role in local invasion and spread of gastric adenocarcinoma and negatively influences survival. However, further studies are required to assess their true usefulness in the clinical practice.
authors.affiliation: Department of General Surgery, Hospital of Ministry of Interior in Lublin.
authors.forename: Jarosław
authors.initials: J
authors.lastname: Bury
authors.forename: Justyna
authors.initials: J
authors.lastname: Szumiło
authors.forename: Andrzej
authors.initials: A
authors.lastname: Dąbrowski
authors.forename: Aleksander
authors.initials: A
authors.lastname: Ciechański
authors.forename: Justyna
authors.initials: J
authors.lastname: Śliwińska
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Wallner
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D011379:Prognosis; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000473:pathology; D000077022:Survivin; D042442:Vascular Endothelial Growth Factors / Q000032:analysis*
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D042442:Vascular Endothelial Growth Factors